logo
Share SHARE
FONT-SIZE Plus   Neg

Strategic Diagnostics Turns To Profit In Q4

Strategic Diagnostics (SDIX: Quote), a biotechnology-based products provider, reported fourth-quarter net income of $1.7 million or $0.08 per share, compared to a net loss of $260,000 or $0.01 per share last year.

Results for the quarter included income from discontinued operations of $3.2 million

Revenues for the quarter declined to $5.5 million from $6.3 million last year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Israeli generic drug maker Teva Pharmaceutical Industries (TEVA) on Tuesday offered to buy smaller Dutch rival Mylan N.V. (MYL) for $82 per share in cash and stock, or about $40 billion, in a bid to further tighten its grip in the global generic space. Twitter is expanding its direct messaging feature to enable users to communicate privately with a single person or with a group of people, even if they are not following each other. High-flying Netflix may have yet another hit on its hands, as the company has ordered a spin-off of the hugely popular Full House series. Fuller House will star Candace Cameron-Bure, Jodie Sweetin and Andrea Barber, who played sisters D.J. Tanner and Stephanie Tanner, and D.J.'s bestie Kimmy Gibbler,...
comments powered by Disqus
Follow RTT